Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country. | The recent decline of Merck & Co.
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Before the Senate's confirmation vote on President Donald Trump’s pick for secretary of the Department of Health and Human ...
When compared against market expectations, Merck’s fourth-quarter results were a mixed bag. The company reported non-GAAP EPS ...
Merck (NYSE:MRK) is scheduled to announce Q4 earnings results on Tuesday, February 4th, before market open. Truist Securities ...
Kennedy’s commitment to walk away from the potential windfall is a major reversal for the nominee, who in his ethics plan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback